非布索坦作用功效

For the treatment of chronic hyperuricemia (gout). Gout occurs because the body produces excessive blood uric acid and the kidneys' reduced ability to eliminate it. Blood uric acid accumulates in the body, causing urate crystals to accumulate in joints and internal organs. The successful development of febuxostat is good news for many patients. So what are the functions and efficacy of febuxostat?

The conversion of uric acid in the body is related to purine metabolism. In the final process of purine metabolism, hypoxanthine is converted into tyrosine under the action of tyrosine oxidoreductase (XOR), and then further converted into uric acid. Inhibiting the activity of this enzyme can effectively reduce the conversion of uric acid.

Febuxostat is a newly developed XOR retarder in the world. It can selectively act on this antibiotic through a high degree of efficiency, reduce the production of blood uric acid in the body, lower cholesterol levels, and thus effectively treat ventilation symptoms.

Since allopurinol is an analogue of pyridine, it is inevitably affected by other enzymatic reactions involving pyridine and pyridine metabolism. Therefore, during allopurinol treatment, repeated large-dose administration is required to maintain a high drug level.

This may also result in serious or even fatal side effects caused by drug accumulation. Febuxostat is a non-pyroxine-based XOR retarder, so it has a stronger safety factor. Allopurinol only has an inhibitory effect on the reduced form of XOR, while febuxostat has a significant inhibitory effect on both air-oxidized and reduced forms of XOR, so its cholesterol-lowering effect is more powerful and long-lasting.

The therapeutic efficacy of febuxostat is also known from clinical trial data. A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of this product was significantly lower than before treatment. According to the dose, each group decreased by an average of 37%. %, 44% and 59%, while the patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial. The incidence of adverse reactions in this product and the placebo group was similar, and most of these adverse reactions were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.

Clinical data shows that the effect of treating gout is very significant. If patients have other questions about the drug, they can consult the medical companion.